Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Neurocrine Biosciences Inc (NBIX) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance

Neurocrine Biosciences IncTrade
Charles Schwab Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Neurocrine Biosciences Inc vs Charles Schwab Corporation Common Stock — how do they compare? Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B), while Charles Schwab Corporation Common Stock trades at $109.34 (market cap $186.25B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 11.3× Neurocrine Biosciences Inc's market cap, and Charles Schwab Corporation Common Stock pays a 1.19% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.

NBIXSCHW
Market Cap
$16.46B$186.25B
Sector
HealthFinancials
52-Week High
$185.50$108.02
52-Week Low
$123.10$85.35
Enterprise Value
$16.48B
Dividend Yield
1.19%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Neurocrine Biosciences Inc

Neurocrine Biosciences (NBIX) trades at $156.49, down 5.11% amid bearish technical signals despite strong fundamentals. The stock shows robust revenue growth with Q2 2026 sales up 39% year-over-year to $959 million, beating earnings estimates. Recent news highlights pipeline advancement with a Phase 1 GLP-1/GIP/glucagon agonist study initiation while facing safety concerns for Vykat XR in Prader-Willi syndrome.

Outlook remains positive with 86% analyst buy ratings and $208.82 consensus target offering 33% upside. Key risks include drug safety scrutiny and execution on pipeline catalysts. Strong institutional interest persists with CalPERS increasing holdings by 13% in Q2 2026, supporting long-term growth narrative amid near-term technical weakness.

Charles Schwab Corporation Common Stock

Charles Schwab (SCHW) trades at $109.28, up 1.19% today, near its all-time high of $109.05 (Zacks Investment Research, 2026-08-07). The stock shows strong momentum with bullish technical signals and consistent earnings beats in recent quarters. Revenue grew to $23.92 billion in 2025, with net income margin expanding to 37%, while analyst consensus is bullish with a $122.33 price target. Recent news highlights insider selling and ongoing litigation, but institutional acquisitions signal confidence.

Outlook remains positive driven by earnings growth and market share gains, but risks include regulatory scrutiny from lawsuits (Business Wire, 2026-08-10) and interest rate sensitivity. The stock offers upside to consensus targets, though overbought conditions suggest potential near-term volatility. Investors should weigh robust fundamentals against macroeconomic and legal headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.

Read more on NBIX

About Charles Schwab Corporation Common Stock

Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.

Read more on SCHW